Biotechnology

Precision Biosciences

Precision Biosciences released FY2026 Q1 earnings on May 5 Pre-Market EST, actual revenue USD 10.84 M (forecast USD 4.05 M), actual EPS USD -0.7499 (forecast USD -0.655)

Precision Biosciences to Release FY2026 Q1 Earnings on May 5, Pre-Market EST; Forecast Revenue USD 4.05M, EPS USD -0.655

Precision Biosciences released FY2025 Q4 earnings on March 12 Pre-Market (EST), actual revenue USD 34.2 M (forecast USD 9.075 M), actual EPS USD 1.0567 (forecast USD -0.535)

Precision Biosciences released FY2025 earnings on March 12 Pre-Market EST, actual revenue USD 34.26 M (forecast USD 9.14 M), actual EPS USD -3.5649 (forecast USD -6.135)

Precision Biosciences to Release FY2025 Q4 Earnings on March 12 Pre-Market EST, Forecast Revenue USD 9.075 M, EPS USD -0.535

Precision BioSciences to Present Chronic Hepatitis B Gene Editing Therapy PBGENE-HBV Clinical Data at Hep-DART 2025

Precision Biosciences released FY2025 Q3 earnings on November 3 During-Market EST, actual revenue USD 0 (forecast USD 5.4 M), actual EPS USD 0 (forecast USD -1.34)

Precision Biosciences released FY2025 9 Months Earnings on November 3 During-Market EST, Actual Revenue: USD 60K, Actual EPS: USD -6.1854

Trucchio's Strong Buy Recommendation for Precision BioSciences

Precision Biosciences to release FY2025 Q3 earnings report on November 3, during market hours EST, with forecast revenue of USD 5.4 M and EPS of USD -1.34

Trucchio Analyst Covers Multiple Healthcare Stocks Including Precision BioSciences

Patrick Trucchio Reiterates Buy Rating on Precision BioSciences

Precision Biosciences released FY2025 Q2 earnings on August 7 During-Market EST, actual revenue USD 18K (forecast USD 6.267M), actual EPS USD -2.1299 (forecast USD -1.5666)

Precision Biosciences released FY2025 Semi-Annual earnings on August 7 During-Market (EST), actual revenue USD 47K, actual EPS USD -4.3351

Precision Biosciences to release FY2025 Q2 earnings report on August 7 During-Market EST, forecast revenue USD 6.267 M, EPS USD -1.5666

Precision BioSciences Advances DMD Gene Editing Therapy into First-in-Human Clinical Trial

Kevin Buehler Acquires Precision BioSciences Inc. Common Stock

Precision BioSciences Receives FDA PBGENE-DMD Therapy Orphan Drug Designation

Precision Biosciences released FY2025 Q1 earnings on May 15 Pre-Market EST, actual revenue USD 29 K (forecast USD 5 M), actual EPS USD -2.2131 (forecast USD -1.7166)

Precision Biosciences Reports Q1 Operating Loss of $22.112 Million

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Micware

Silexion Therapeutics

BiomX

MicroAlgo

MetaVia

Tradr 2X Long XNDU Daily ETF

Vida Global

DTIL

LABU

iECURE, Inc. presented preliminary clinical data at the ASGCT Annual Meeting regarding its ongoing OTC-HOPE trial for ECUR-506 in treating ornithine transcarbamylase (OTC) deficiency. The data showed that 71% of participants experienced no hyperammonemic crises (HACs) post-treatment, with a 52% reduction in the annualized rate of HACs. ECUR-506 was well tolerated, with no unexpected safety events. The findings suggest potential improvements in clinical outcomes for infants suffering from this serious genetic disorder, highlighting the need for new treatment approaches.

StockTitan

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting | DTIL Stock News

COGT

IBBQ

SBIO

Colossal Biosciences has announced that its de-extinct dire wolves, Romulus, Remus, and Khaleesi, are now breeding-aged, with plans to expand the pack later this year. The company aims to create a sustainable population of the world's first de-extinct species through assisted reproduction and natural breeding. Colossal is also pursuing several other de-extinction projects, including the woolly mammoth, thylacine, dodo, and moa, while emphasizing ethical animal welfare and conservation goals. Critics raise concerns about genetic editing and ecological risks, but the company continues to attract global attention for its innovative biotechnology efforts.

ZeroHedge

MBX Biosciences

Cogent Biosciences

VG Health

iShares Biotechnology ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

ALPS Medical Breakthrough

De-Extinct Dire Wolves Ready To Breed; Bioscience Company Pushes Forward Multiple Projects

ALLO

Alpenglow Biosciences has launched Summit AI, a multimodal AI platform for quantitative analysis of whole tissue imaging in dermatology. This platform converts complex imaging data into structured spatial readouts while maintaining the original image context. Initially focused on inflammatory skin diseases, Summit AI aims to enhance tissue analysis by providing comprehensive insights into tissue architecture and disease states. It integrates 3D imaging with 2D readouts and includes uncertainty metrics to improve confidence in model outputs, supporting drug development and clinical diagnostics.

Unusual Whales

Allogene Therapeutics

iShares Global Healthcare

Alpenglow Biosciences Introduces Summit AI for Quantitative Analysis of Whole Tissue Imaging in Dermatology

Earnings Watch

Precision Biosciences | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 10.84 M

Precision Biosciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 10.84 M

VXRT

Altesa BioSciences has enrolled its first patient in the Phase 2b CARDINAL clinical trial, evaluating vapendavir as a treatment for COPD patients affected by rhinovirus. The trial aims to demonstrate that vapendavir can alleviate respiratory symptoms and improve lung function compared to placebo. With 900 participants in the US and UK, the study will assess symptom improvement and other health outcomes. Vapendavir is an investigational antiviral drug targeting rhinovirus, which is responsible for many COPD exacerbations. The trial reflects a shift towards addressing the underlying causes of respiratory infections.

prnewswire

Vaxart

GlaxoSmithKline plc

GSK plc Sponsored ADR

07:00 ETAltesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations

Precision BioSciences reported its Q1 2026 financial results, highlighting advancements in its clinical trials for PBGENE-HBV and PBGENE-DMD. The company has a cash balance of $125.8 million, expected to support its gene editing programs through 2028. The PBGENE-HBV trial is progressing with new cohorts, and a late-breaking poster presentation is scheduled for the EASL Congress 2026. Additionally, the first clinical site for PBGENE-DMD has been activated, with patient enrollment underway. The company aims to achieve significant clinical milestones in 2026.

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update | DTIL Stock News

Precision Biosciences(DTIL.US)